692 reports of this reaction
6.6% of all BUROSUMAB reports
#1 most reported adverse reaction
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #1 most commonly reported adverse reaction for BUROSUMAB, manufactured by Kyowa Kirin, Inc.. There are 692 FDA adverse event reports linking BUROSUMAB to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 6.6% of all 10,519 adverse event reports for this drug.
Patients taking BUROSUMAB who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is moderately reported among BUROSUMAB users, representing a notable but not dominant share of adverse events.
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for BUROSUMAB:
The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 692 FDA reports for BUROSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 6.6% of all adverse event reports for BUROSUMAB, making it one of the most commonly reported side effect.
If you experience inappropriate schedule of product administration while taking BUROSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.